Ineffective erythropoiesis and its treatment.
Cazzola M.
Blood. 2022 Apr 21;139(16):2460-2470. doi: 10.1182/blood.2021011045.
Mitochondrial Fragmentation Triggers Ineffective Hematopoiesis in Myelodysplastic Syndromes.
Aoyagi Y, Hayashi Y, Harada Y, Choi K, Matsunuma N, Sadato D, Maemoto Y, Ito A, Yanagi S, Starczynowski DT, Harada H.
Cancer Discov. 2022 Jan;12(1):250-269. doi: 10.1158/2159-8290.CD-21-0032. Epub 2021 Aug 30.
Targeting ineffective hematopoiesis in myelodysplastic syndromes.
Patnaik MM, Santini V.
Am J Hematol. 2022 Feb 1;97(2):171-173. doi: 10.1002/ajh.26416. Epub 2021 Nov 28.
Epidemiology and Pathogenesis of Myelodysplastic Syndrome.
Rotter LK, Shimony S, Ling K, Chen E, Shallis RM, Zeidan AM, Stahl M.
Cancer J. 2023 May-Jun 01;29(3):111-121. doi: 10.1097/PPO.0000000000000665.
Unraveling the mechanisms behind iron overload and ineffective hematopoiesis in myelodysplastic syndromes.
Angelucci E, Cianciulli P, Finelli C, Mecucci C, Voso MT, Tura S.
Leuk Res. 2017 Nov;62:108-115. doi: 10.1016/j.leukres.2017.10.001. Epub 2017 Oct 5.
Germline DDX41 mutations cause ineffective hematopoiesis and myelodysplasia.
Chlon TM, Stepanchick E, Hershberger CE, Daniels NJ, Hueneman KM, Kuenzi Davis A, Choi K, Zheng Y, Gurnari C, Haferlach T, Padgett RA, Maciejewski JP, Starczynowski DT.
Cell Stem Cell. 2021 Nov 4;28(11):1966-1981.e6. doi: 10.1016/j.stem.2021.08.004. Epub 2021 Sep 1.
Hereditary disorders of ineffective erythropoiesis.
King RA, Khoriaty R.
Blood Cells Mol Dis. 2025 Mar;111:102910. doi: 10.1016/j.bcmd.2025.102910. Epub 2025 Feb 7.
Iron-Loading Anemias.
Levy MV, Ginzburg YZ.
Adv Exp Med Biol. 2025;1480:145-161. doi: 10.1007/978-3-031-92033-2_11.
Myelodysplastic syndromes.
Adès L, Itzykson R, Fenaux P.
Lancet. 2014 Jun 28;383(9936):2239-52. doi: 10.1016/S0140-6736(13)61901-7. Epub 2014 Mar 21.
Therapy-related myelodysplastic syndrome.
Candelaria M, Dueñas-Gonzalez A.
Expert Opin Drug Saf. 2015 May;14(5):655-65. doi: 10.1517/14740338.2015.1014340. Epub 2015 Feb 12.
